1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. đť•Ź Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. đť•Ź Posts
Discussion
1. Investment Snapshot
2. Valuation
Discussion
Symbol
HLXC
Event Date
2026-01-23
Sector
Financials
Subsector
Blank Check / SPAC
Offer Range
$10.00
Shares Offered
15M
$185.8M
Implied Upside vs Midpoint
Description
We are a blank check company incorporated on September 10, 2025, as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. --- Consistent with our business strategy, we expect to identify companies that have compelling growth potential and a combination of the following characteristics. We will seek to acquire companies or assets with a significant share of the following characteristics: • rigorous science that includes a unique insight or a novel approach coupled to targets with clear, simple therapeutic rationale; • compelling data indicating a drug candidate or platform is likely to generate a differentiated therapeutic for patients suffering from serious disease and with unmet need; • nimble critical path to generate data that will advance one or more drug candidates through research, clinical, or regulatory milestones and value step-ups; • the right management team with requisite experience and skills to develop and commercialize the most compelling drug candidates and that will benefit from our capital, advice, and network; and • an attractive valuation that traces to being overlooked as too early, misunderstood due to complex science, or undercapitalized and that can offer near-term liquidity and significant upside for investors. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may deem relevant. We may decide to enter into our initial business combination with a target business that does not meet the above criteria and guidelines. --- Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA 02116, and our telephone number is +1 (857) 702-0370.